VFS
ZVRA icon

VSR Financial Services’s Zevra Therapeutics ZVRA Stock Holding History

VSR Financial Services’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-648
Closed -$150K – 594
2016
Q1 		$150K Hold
648
– – 0.02% 530
2015
Q4 		$206K Buy
+648
New +$176K 0.02% 521

Other funds holding ZVRA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

VSR Financial Services's ZVRA Position: Q2 2016 in Review

VSR Financial Services sold out of Zevra Therapeutics (ZVRA) in Q2 2016, closing a stake of 648 shares — an estimated $150K sold.

VSR Financial Services first reported a position in ZVRA in Q4 2015 and held it in 2 quarters. The position peaked at $206K in Q4 2015. 40 funds tracked by Wall St. Rank hold ZVRA as of Q2 2016.

  • VSR Financial Services reported no remaining Zevra Therapeutics position as of Q2 2016 after selling out during the quarter.
  • VSR Financial Services sold 648 Zevra Therapeutics shares in Q2 2016, an estimated $150K.
  • VSR Financial Services first reported a position in Zevra Therapeutics in Q4 2015 and held it in 2 quarters.
  • VSR Financial Services's Zevra Therapeutics position peaked at $206K in Q4 2015.
  • 40 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2016.

Based on VSR Financial Services's 13F filing for Q2 2016, filed 11 Aug 2016.